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ABSTRACT
mRNA stability is emerging as a fundamental and effective cellular tool to
regulate gene expression at posttranscriptional levels. mRNA stability is controlled
via orchestrated interactions between mRNA structural components (cis-elements)
and specific trans-acting factors. The most widespread and efficient determinant of
RNA stability are the adenylate and uridylate-rich elements (ARE) that, through
binding of ARE-binding proteins (AUBPs), modulate the stability of transcripts
and/or their translation. Alterations in any of these components can lead to disease.
Here, we review the genetic alterations in 3’UTR regulatory sequences as well as
the aberrant levels, subcellular localization, and posttranslational modifications
of AUBPs that are linked to human diseases. A thorough understanding of these
alterations and their impact on mRNA stability regulation will uncover promising
new targets for therapeutic intervention.
Key words: Post-transcriptional gene regulation.—RNA-binding proteins.—AU-
rich elements (ARE).—ARE-binding proteins (AUBPs).—Cancer.—Inflammation.—
Thalassemia.—Alzheimer disease.
* Corresponding authors:
Isabel López de Silanes: ilsilanes@cnio.es
Manel Esteller: mesteller@cnio.es
Cancer Epigenetics Laboratory, Spanish National Cancer Center (CNIO).
Melchor Fernández Almagro, 3 - 28029 Madrid (Spain).
Telf.: +34 91 224 20 27. Fax: +34 91 224 69 23.
ISABEL LÓPEZ DE SILANES Y MANEL ESTELLER AN. R. ACAD. NAC. FARM.
564
RESUMEN
Regulación anormal de la estabilidad del ARNm en enfermedades humanas
La estabilidad del ARN mensajero está surgiendo como instrumento celular
fundamental y efectivo para regular la expresión génica a nivel post-transcripcio-
nal. La estabilidad del ARNm se controla vía interacciones coordinadas entre com-
ponentes estructurales del ARNm (elementos cis) y factores trans específicos. Los
determinantes de estabilidad de ARNm más conocidos y eficientes son los elemen-
tos ricos en adenina y uridina (ARE) que, a través de su unión con proteínas de
unión a ARE (AUBPS), modulan la estabilidad de los transcritos y/o su traducción.
Alteraciones en cualquiera de estos componentes puede dar lugar a enfermedades.
Aquí revisamos las alteraciones genéticas en elementos regulatorios del 3’UTR, así
como las aberraciones en los niveles, localización subcelular y modificaciones post-
traslacionales de AUBPs que están asociadas a enfermedades humanas. Un cono-
cimiento detallado de estas alteraciones y su impacto en la regulación de la esta-
bilidad del ARNm revelará nuevas dianas para su aplicación terapéutica.
Palabras clave: Regulación génica post-transcripcional.—Proteínas de unión a
ARN.—Elementos enriquecidos en AU (ARE).—Proteínas de unión a ARE (AUBPs).—
Cáncer.—Inflamación.—Talasemia.—Enfermedad de Alzheimer.
INTRODUCTION
The regulation of gene expression is a fundamental cellular
process that is controlled at multiple levels. While the study of gene
regulation has traditionally focused on transcription as a major
regulator of gene expression, it has recently become apparent that
the posttranscriptional control of gene expression may play an
equally important role. Posttranscriptional events comprise pre-
mRNA processing, nucleo-cytoplasmic export, mRNA localization,
mRNA stabilization and translational regulation (1). Due to the
impact that each of these steps can have on gene expression, each of
them is tightly regulated. The mechanisms underlying this regulation,
still poorly understood, involve mRNA structural components (cis
elements) and trans-acting factors [primarily RNA-binding proteins
and non-coding RNAs (e.g., miRNAs)]. Therefore, alterations in any
of these levels can have a profound impact on global RNA levels
and have been related to numerous pathologies including cancer,
inflammatory and autoimmune diseases, developmental defects, and
neurodegenerative diseases (2-5).
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The posttranscriptional processes that affect the mRNA are
regulated by the orchestrated interactions between mRNA structural
components (cis elements) and specific trans-acting factors. Well-
characterized RNA sequence elements can be found throughout the
body of mRNAs including the 5’-untranslated region (5’UTR), the
coding region, and the 3’UTR (Fig. 1A). Most RNA sequence elements
[e.g., the 5’-cap structure and the 3’poly(A) tail] are universally
present in all mRNAs and direct constitutive processes without
apparent selectivity of one mRNA relative to another. However,
specific RNA elements have been identified which affect the stability
and/or translation of given subsets of mRNAs. The vast majority of
such specific RNA sequences are present in the 3’UTR; among them,
the best characterized are regions rich in adenine and uridine
residues known as AU-rich elements (ARE). AREs have been
identified in the 3’UTR of a variety of short-lived mRNAs, including
those encoding oncogenes and growth factors, cell-cycle regulatory
proteins, cytokines, and inflammatory mediators. AREs frequently,
though not always, contain a variable number of AUUUA pentamers,
sometimes harbored within a U-rich region. The canonical motifs
identified for RNA-biding proteins HuR and TIA-1 (6, 7) consist of
a combination of primary sequence and secondary structure in the
3’UTR. AREs are well known to influence stability and are
increasingly recognized to affect translation (8, 9). The RNA levels
of many of ARE-containing mRNAs are altered in pathological
situations such as cancer and inflammation due to abnormal mRNA
stabilization and /or translation processes. It is crucial, therefore, to
understand the regulation of these «ARE-containing genes» because
of their demonstrated involvement in human diseases (2-5).
Cis-elements serve as binding sites for a variety of RNA-binding
proteins that modulate posttrancriptionally mRNA levels. Of
particular interest for this review is the family of RNA-binding
proteins that associate to the ARE-determinants (AUBPs). AUBPs
regulate, among other processes, the mRNA stability (in a positive
way such as the mRNA-stabilizing HuR or negative, like the mRNA-
destabilizing AUF1 and TTP) and translation (e.g., TIA inhibiting
translation or HuR, enhancing mRNA translation) of ARE-containing
mRNAs. At least 12 ARE-BPs (see Table 1) have been identified so
far. Most AUBPs are predominantly nuclear proteins that shuttle
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FIGURE 1. mRNA stability determinants and their alterations in human
diseases. (A) Schematic of the different regions in the mRNA. The 3’UTR is
enlarged to show the cis-elements (e.g., AREs) that are found in this region and
the trans-acting factors (e.g., AUBPs, and miRNA) that associate to them. (B) In
defective cells, two main groups of alterations affect mRNA stability and/or
translation: 1) Genetic alterations in ARE such as mutations, deletions,
translocations and polymorphisms and 2) Altered regulation of AUBPS such as
global increase of AUBS, changes in their subcellular localization (e.g., increased
cytoplasmic levels of AUBPs in cancer), aberrant pattern of posttranslational
modifications (e.g., phosphorylation) and altered competition for binding between
AUBPs. AUBPs: AU-rich binding proteins. ARE: AU-rich elements. miRNA:
microRNAs.
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between the nucleus and the cytoplasm. Their cytoplasmic presence
appears to be intimately linked to their influence upon target mRNAs
and hence AUBPs localization has been the subject of gene
expression studies, specially in cancer. AUBS are also targeted for
posttranslational modifications, influencing AUBP ability to bind
to target mRNAs as well as their subcellular location. Increasing
evidence supports the notion that several RNA-binding proteins can
bind to a common ARE-containing target mRNA on both distict,
nonoverlapping sites, and on common sites in a competitive fashion.
It is becoming increasing apparent that the composition and fate
(stability, translation) of ribonucleoprotein complexes depend on
the target mRNA of interest, RNA-binding protein abundance, stress
conditions, and subcellular compartment. While AUBPs regulate
numerous posttranscriptional aspects of the mRNA (such as splicing,
mRNA localization, and mRNA storage), this review will focus on
the literature describing their influence on mRNA stability and
translation (8-10).
Given the aforementioned involvement of 3’UTR cis-elements and
trans-acting factors in dictating mRNA stability and translation,
it is easy to envision how alterations in any of these components
can have a major impact on mRNA half-life and/or translation.
In turn, defective mRNA turnover can cause abnormal stabilization
or decay of mRNAs, while disregulated translation can elevate or
lower translation rates. Together, these anomalous processes will
result in aberrant levels of expressed protein and hence metabolic
changes leading to disease. Defective mRNA half-life and translation
can arise from 1) Mutations in regulatory cis-elements (e.g., AREs)
such as single-point mutations, large deletions/insertions and
polymorphisms, and 2) alterations in trans-acting factors (e.g.,
AUBPs) such as defective expression and/or subcellular localization
of trans-acting factor, altered pattern of posttranslational
modifications, and aberrant competition among AUBPs which will
ultimately influence their net influence upon the fate of the mRNA
(stabilization, translation) (Fig. 1B). In human diseases, alterations
in both cis-elements and trans-acting factors have been described
(2-5). The purpose of this review is, therefore, to examine the altered
mRNA stability and/or translation regulation mediated, mainly, by
ARE determinants that can be found in human diseases. Identifying
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such alterations and studying how they modify cell biology will help
to better understand the mechanisms involved in human diseases
and will facilitate the development of novel therapeutic modalities.
TABLE 1. List of AU-rich binding proteins (AUBPs)
Gene Symbol &
(Ref Seq)
ELAVL1
(NM_001419)
ELAVL2
(NM_004432)
ELAVL3
(2 isoforms:
NM_001420;
NM_032281)
ELAVL4
(NM_021952)
hnRNPD
(4 isoforms:
NM_031370;
NM_031369;
NM_002138;
NM_001003810)
Subcellular
localization
Mainly nuclear
(ubiquitous)
Mainly nuclear
(neuronal and
sex glands)
Mainly nuclear
(neuronal)
Mainly nuclear
(neuronal)
Isoforms p42
and p45 are
nuclear; p37
and p40,
nucleo-
cytoplasmic
Function
mRNA
stabilization
(1),
translational
enhancer (2)
mRNA
stabilization
(1),
translational
enhancer (2)
mRNA
stabilization
mRNA
stabilization
(1),
translational
enhancer (2)
mRNA
destabilizing
Target mRNAs
(examples)
c-fos (1), c-myc
(1), p21 (1),
COX-2 (1),
TNF-α (1),
cyclin A, B1, D1
(1), iNOS (1),
IL-3 (1), MyoD
(1), p53 (2)
GLUT1 (1 and
2), NF-M (2)
VEGF, c-myc
GAP-43 (1),
MARCKS (1),
Msi-1 (1 and 2)
c-myc, GM-CSF,
cyclin D1,
GADD45, bcl-2,
cyclin D1
RNA-
binding
protein
HuR
HuB
HuC
HuD
AUF1
Official name
ELAV
(embryonic
lethal,
abnormal
vision,
Drosophila)-
like 1 (Hu
antigen R)
ELAV
(embryonic
lethal,
abnormal
vision,
Drosophila)-
like 2 (Hu
antigen B)
ELAV
(embryonic
lethal,
abnormal
vision,
Drosophila)-
like 3 (Hu
antigen C)
ELAV
(embryonic
lethal,
abnormal
vision,
Drosophila)-
like 4 (Hu
antigen D)
heterogeneous
nuclear
ribonucleo-
protein D
Numbers in brackets of each individual target mRNAs refer to the matched function shown for each
specific RNA-binding protein.
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TABLE 1. List of AU-rich binding proteins (AUBPs) (cont.)
Gene Symbol &
(Ref Seq)
Subcellular
localization Function
Target mRNAs
(examples)
RNA-
binding
protein
Official name
Numbers in brackets of each individual target mRNAs refer to the matched function shown for each
specific RNA-binding protein.
TTP
TIA-1
TIAR
KSRP
BRF1
NF90
CUG-
BP2
Tristetraprolin
cytotoxic
granule-
associated RNA
binding protein
TIA1 cytotoxic
granule-
associated RNA
binding
protein-like 1
KH-type
splicing
regulatory
protein
zinc finger
protein 36,
C3H type-
like 1
interleukin
enhancer
binding factor
3, 90kDa
CUG triplet
repeat, RNA
binding
protein 2
TTP
(NM_003407)
TIA1
(NM_022173)
TIAL1
(NM_003252)
KHSRP
(NM_003685)
ZFP36L1
(NM_004926)
ILF3
(3 isoforms:
NM_004516;
NM_012218;
NM_153464)
CUGBP2
(3 isoforms:
M_001025076;
NM_001025077;
NM_006561)
Nuclear (20%)
and
cytoplasmic
(80%)
Mainly nuclear
Mainly nuclear
Mostly nuclear
Nuclear and
cytoplasmic
Mainly nuclear
Mainly nuclear
mRNA
destabilizing
(1), decapping
(2)
Translational
represor (1),
alternative
RNA
processing (2)
Translational
represor (1),
alternative
RNA
processing (2)
mRNA
destabilizing
(1), RNA
splicing (2)
mRNA
destabilizing
mRNA
stabilization
(1),
Translational
represor (2)
RNA editing
(1), mRNA
stabilization
(2) and
translational
silencer (3)
PAI-2 (1),
TNF-α (1),
COX-2 (1),
GM-CSF (2)
COX-2 (1),
TNF-α (1),
Fos (2)
IL-8 (1), iNOS
(1), β2-AR (1),
GADD45 (1),
calcitonin/
CGRP (2)
c-fos (1), c-jun
(1), IL-2 (1),
TNF-α (1), iNOS
(2)
cIAP2, IL-3
IL-2 (1), acid
beta-
glucosidase (2)
Apolipoprotein
B (1), COX-2
(2 and 3)
DEFECTIVE mRNA STABILITY REGULATION IN HUMAN
DISEASES
Several human diseases, outlined below, are associated to
mutations in 3’UTR mRNA stability determinants or to alterations in
the regulation of 3’UTR-binding regulatory proteins. Next, specifics
examples will be given to illustrate both aspects.
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Cancer
In cancer, most studies have sought to identify mutations in the
coding region and very few naturally occurring mutations in
noncoding areas have been described to date. Genetic alterations
in 3’UTR sequences can modify the binding properties of trans-acting
factors and lead to deregulation in protein production. The examples
below illustrate the importance of the genetic alterations in AREs in
promoting malignancy and its usefulness in determining cancer
therapy. The first example described was for the oncogene c-fos and
its viral counterpart v-fos. The coding region of both c-fos and v-fos is
identical differing only in a missing 67-bp (that contains a ARE) in the
v-fos 3’UTR. Consequently, v-fos mRNA is more stable than
c-fos mRNA and this may account in part for its higher oncogenic
potential (11). Other naturally alteration in AREs have been described
such as the disruption of the 3’UTR during the integration of Human
papillomavirus type 16 (HPV-16), 3’UTR rearrangement of Cyclin D1
and translocation and deletion of ARE in the proto-oncogene c-myc,
all of them linked to malignant transformation. 3’UTR polymorphism
also affect mRNA stability as it has been found for the thymidylate
synthase (TYMS) gene. The polymorphism in the 3’UTR consists of the
deletion (D)/insertion (I) of a 6-bp stretch (TTAAAG). The D allele
showed decreased message stability compared to the I allele due to
increased binding to the decay-promoting protein AUF1 (12). In
agreement with this finding, colorectal tumors from D-allele carriers
have decreased intratumoral TYMS mRNA levels (13) suggesting that
the 3’UTR polymorphism can have an impact on the efficiency of
TYMS-targeted chemotherapy treatment. Another relevant example is
a novel single-nucleotide polymorphism (SNP) in the human
dihydrofolate reductase (DHFR) gene that influences mRNA
expression levels as well.
Other commonly found alteration in cancer is the frequently
elevated levels of RNA-binding proteins as it has been documented
for the mRNA-stabilizing protein HuR, and the destabilizing AUF1
and TTP in a wide variety of malignancies (6, 14-16). Depending on
the type of tumor, AUBPs with similar functions (e.g., AUF1 and
TTP) can have oncogenic or tumor suppressor activities (15, 16).
These studies suggest that AUBP play a central role in cancer by
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binding to mRNAs encoding proteins involved in malignant
transformation, and inducing or repressing their expression by
altering mRNA stability and/or translation rates. Moreover, the
cytoplasmic abundance of AUBPs (e.g., HuR and AUF1) increases
with malignancy (6, 17). This is particularly relevant since the
cytoplamic presence of AUBPs seems to be linked to its stabilizing/
destabilizing function. Wnt activation, the tumor suppressor protein
von Hippel Lindau (VHL), and AMP-activated protein kinase (AMPK)
are responsible for the cytoplasmic distribution of AUBPs and
their pathways are also altered in cancer (18-20). Posttranslational
modifications of RNA-binding proteins can affect their ability to
bind to target mRNAs as well as their subcellular location as it
has been shown with the phosphorylation of AUF1 and KSRP. Cell
signaling events may also alter mRNA stability, translation and AUBP
abundance. For instance, the MAPK pathway affects mRNA stability
and translations through the differential phosphorylation of RNA-
binding proteins (21). Importantly, several RNA-binding proteins can
bind to a common ARE-containing target mRNA on both distict,
nonoverlapping sites, and on common sites in a competitive fashion.
For instance, IL-8 plays an integral role in promoting the malignant
phenotype in breast cancer and its production is directly influenced
by inflammatory cytokines in the tumor microenvironment. In
keeping with this notion, activation of the IL-1 receptor on malignant
breast cancer cells strongly induced IL-8 mRNA levels. HuR, KSRP
and TIAR were found to bind to one or more locations within the IL-
8 3’UTR although the association of the stabilizing factor HuR was
20-fold greater than that of the destabilizing factor KSRP (22).
Inflamation and autoimmunity
Several proteins that are encoded by ARE-containing transcripts
are critical components of the effector phase of inflammatory
and autoimmune diseases. Of particular importance is tumor
necrosis factor α (TNF-α), one of the principal mediators of the
inflammatory response in mammals. In addition to its well-known
role in acute septic shock, it has been implicated in the pathogenesis
of graft-versus-host disease, rheumatoid arthritis, Crohn’s disease,
and the cachexia that accompanies cancer and the acquired
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immunodeficiency syndrome. Many evidences supports the impact
of ARE sequences on the posttranscriptional regulation of TNF-α
biosynthesis. Macrophages from mice with a genomic deletion of
the TNF-α ARE exhibit spontaneous production of TNF-α and their
TNF-α mRNA has a substantially prolonged half-life. Remarkably,
they also spontaneously develop a chronic inflammatory arthritis
and Crohn’s disease-like intestinal inflammation. In these studies, it
was shown that the absence of ARE-dependent translational control
of TNF mRNA was associated with the inability of p38/SAPK and
JNK/SAPK signalling pathways to regulate its translational
activation. The binding of a number of AUBPs to the ARE sequences
are directly responsible of the destabilization of the TNF-α mRNA.
TIA-1 and TTP are AUBPs that prevent the pathological expression
of tumor necroris factor alpha, TIA inhibiting its translation and
TTP promoting the degradation of TNF-α transcripts and, in turn,
functioning as arthritis suppressor genes (23). Therapies such as
neutralizing antibodies to TNF-α and chimeric soluble TNF-α
receptor have demonstrated efficacy against some of these conditions
in clinical trials. Furthermore, the TNF-α ARE is also known to
be a target for the mRNA stabilizing factor HuR, and mutations
of this cis-element both impair HuR binding and decrease TNF-α
protein production. Post-transcriptional mechanisms also regulate
the production of other proteins involved in inflammatory responses
such as cyclooxygenase-2 (COX-2) and matrixmetalloproteinase-13
(MMP-13). Pharmacologic inhibitors of COX-2 are potent, anti-
inflammatory agents, which significantly reduce the severity of
inflammatory arthritis.
Polymorphisms in the 3’UTR of multiple immune related mRNAs
are also associated with the development of human autoimmune
disease. For instance, deficient TCR ζ chain on the T cells of patients
with systemic lupus erythematosus appears to be due to an
alternatively spliced form of the ζ chain mRNA that has reduced
stability. As a consequence, these cells display abnormal TCR-
induced early signaling and have diminished IL-2 production (3).
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Thalassemia
Thalassemia is a hereditary anemia resulting from defects in
hemoglobin production. It is considered the most common genetic
disorder worldwide. Thalassemia is clinically heterogeneous because
multiple genetic lesions have been described to variably impair
globin-chain synthesis. In the normal adult, hemoglobin A, which is
composed of two alpha and two beta globins (α2β2), is the most
prevalent, comprising about 95% of all hemoglobin. The thalassemias
are classified according to which chain of the globin molecule is
affected. An α-globin gene variant, a constant spring (α cs), is the
most common cause of nondeletional α-thalassemia worldwide. The
α cs mutations harbors a single nucleotide substitution at the wild-
type α-globin mRNA (α WT) translational stop codon (UAA to CAA).
This mutation allows the ribosomes to translate into the normally
ribosome-free 3’UTR, causing a major decrease in α-globin mRNA
half-life. Searching for the mechanisms responsible for the
accelerated decay of the α cs mRNA, Morales and colleagues found
that the α cs mRNA poly(A) tail was significantly shorter that the α WT
mRNA poly(A) tail. Therefore, reduced α cs mRNA half-life appeared
to be linked to accelerated 3’ terminal deadenylation (24). Moreover,
insertion of a stop codon into the α cs immediately upstream of the
α cs mutation prevented ribosome entry into the 3’UTR and stabilized
the α cs mRNA. This data supported a model in which a stability
determinant was present in the 3’UTR and could be affected by the
elongating ribosome (25). In fact, analysis of this region identified
three cytosine-rich (C-rich) segments [also known as pyrimidin-rich
element (PRE)] that contributed to α-globin mRNA stability when
studied in transfected erythroid cells. Subsequently in vitro studies
demonstrated assembly of a sequence-specific ribonucleic-protein
(RNP) complex at this site. Members of the α-globin poly(C)-binding
protein (αCP) were identified as essential protein components of
the α-complex. In patients who have the α cs mutant, read through
translation of the 3’UTR prevents the PCBPs from binding to the
C-rich elements. In vitro studies suggested that additional proteins
may also contribute to α-complex structure and/or function. Of
particular interest was the identification of the ARE binding/
degradation factor AUF1 and poly(A)-binding protein (PABP) as an
interacting partners of αCPs (25).
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Alzheimer disease
Dysregulated synthesis and deposition of extracellular amyloid-
beta (Aβ) within the central nervous system is a major characteristic
of Alzheimer disease (AD). Aβ is derived from proteolytic processing
of one of multiple amyloid precursors protein (APP) isoforms.
Cleavage of the APPs generates the β/A4 peptide, the major
component of amyloid in senile plaque. In addition to the altered Aβ
levels, APP mRNA levels are elevated in brain tissue of AD patients,
and transgenic mice that overexpress APP mRNA and protein have
accelerated Aβ deposition. The 3’UTR of APP mRNA contains a
contiguous 29-base C + U-rich region that appears necessary and
sufficient to control the degradation of the mRNA. Purification
studies identified two RNA-binding proteins that recognize the APP
sequence element (26). One is nucleolin and the other the
heterogeneous nuclear ribonucleoprotein C (hnRNP C), a nuclear
protein that binds U-rich RNA sequences. In cell-free mRNA decay
assays, addition of nucleolin accelerates degradation of APP mRNA,
while addition of hnRNP C stabilizes APP mRNA (27). Recently,
immunohistochemical studies have found the presence of other
AUBPs, hnRNP A2 and B1, in brains of patients with AD. In any
event, like ARE-mRNAs, the cellular decay rate of APP mRNA may
reflect a competition between destabilizing versus stabilizing
proteins. One might envision that tipping the balance to stabilization
might predispose neural tissue to APP overproduction and possibly
AD (28).
Viral infections
The ability to regulate cellular gene expression is a key aspect of
the life-cycles of a diverse array of viruses. In fact, viral infection
often results in a global shutoff of host cellular gene expression,
being host and viral mRNA stability control critical during viral
infection. For instance, simple herpes virus (HSV-1) achieves host-
shutoff through the complementary actions of two viral proteins,
ICP27 and virion host shutoff (vhs), that inhibit cellular mRNA
biogenesis and trigger global mRNA decay, respectively. Although
most cellular mRNAs are thus depleted, some instead increase in
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abundance after infection; perhaps surprisingly, some of these
contain AU-rich instability elements (AREs) in their 3'-untranslated
regions. ARE-containing mRNAs normally undergo rapid decay;
however, their stability can increase in response to signals such as
cytokines and virus infection that activate the p38/MK2 mitogen-
activated protein kinase (MAPK) pathway. HSV-1 infection stabilizes
the ARE mRNA encoding the stress-inducible IEX-1 mRNA. Whether
the IEX-1 mRNA stabilization is carried out by vhs or through the
activation of p38 by ICP27 remains to be clarified (29).
The presence of AU-rich elements in the 3’UTR of viral genomes
adds an additional level of regulation. Thus, direct interactions
between RNA-binding proteins and viral RNA can alter viral RNA
stability and viral protein expression in a manner favorable for viral
survival. AU-rich elements have been identified in the late 3’UTR of
the human papilloma virus (HPV-1) and HPV31 genomes, in the E6
and E7 oncogenes of HPV-16, in the 3’UTR of hepatitis C virus and
certain alpaviruses and in the 5’UTR AU-rich region of the gag gene
of human immmunodeficiency virus (HIV-1). Several of these regions
are binding sites for HuR and the stability of the RNAs is inversely
proportional to the levels of cellular HuR expression (30).
Other diseases
Alterations in the regulation of mRNA stability processes in other
types of diseases have been reported as well. For instance, mutations
that increase mRNA degradation provoking the absence of factor
VIII mRNA (F8) in haemophilia A (31); binding of the Y box-binding
factor-1 (YB-1) to ARE in GM-CSF mRNA, enhancing GM-CSF-
dependent survival of eosinophils that are central in the pathogenesis
of asthma (32); polymorphisms between 2 ARE that increase protein
binding to the allele ARE2, causing a faster degradation of PPP1R3
mRNA that, in turn, lowers the concentration of the protein
implicated in insulin resistance, and thus increasing the risk for
development of type 2 diabetes (33); and finally, it has been found
reduced expression of sGC subunits in animal models of genetic
hypertension because of reduced binding to the mRNA-stabilizing
protein HuR compared to normal animals (34).
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mRNA STABILITY AS A TARGET FOR THERAPY
By gaining a more detailed knowledge of the 3’UTR regulatory
sequences and the trans-acting factors specifically binding to them
it will be possible to design effective therapies. As noted earlier, a
6-bp polymorphism in the 3’UTR of thymidylate synthase decreases
mRNA levels (13) and, thereby could be useful in predicting the
efficacy of TYMS-targeted chemotherapy treatment. TNF-α is
effective in the treatment of advanced solid tumors such as
melanoma and soft tissue sarcoma. When analyzing mRNA levels
of 22 genes in tumor biopsies from patients treated with doxorubicin
alone or combined with TNF-α, TIA-1 was the only gene differentially
expressed between the two groups. When TNF-α effects were tested
in vitro in endothelial cells, fibroblasts, CTLs and NK cells, TIA-1
became upregulated only in endothelial and NK cells. These findings
could indicate that TNF-α -induced TIA-1 overexpression might
sensitize endothelial cells to proapoptotic stimuli present in the
tumor microenvironment and enhance NK cell cytotoxic activity
against cancer cells (35). The chemotherapeutic agent Prostaglandin
A2 (PGA2) causes growth arrest associated with decreased cyclin D1
in several cell lines. PGA2 leads to the destabilization of cyclin
D1 mRNA via a 3’UTR element that binds the RNA-binding protein
AUF1 (36). These studies underscore the potential importance of
understanding 3’UTR regulation in cancer therapy.
Alteration on mRNA stability rates might possibly be cured
by pharmacological approach by correcting the stabilization/
degradation mRNA rates. The specific approach, eventually, would
be targeting the correct mRNA since AUBPs bind to a wide variety
of mRNA targets and exogenous compound might affect a broad
array of genes. If there is an increased in mRNA stabilization, in
order to deacrease the RNA levels, the ARE subregion can be targeted
by antisense oligodeoxynucleotides (ODNs) or ribozymes. By
contrast, when the mRNA is destabilized by mutations or altered
binding to RNA degradation-promoting AUBPs, synthetic
oligoribonucleotides (ORNs) are worth considering since they do not
activate catabolic processes like ODNs. The hybridization of ORN to
ARE sequences might insulate/protect ARE from «contact» with
cellular trans-acting factors (AUBPs) and the exosome (machinery
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responsible for mRNA degradation). More interesting will be the use
of sense-oriented ORNs that are no supposed to interact with the
homologous RNA but might compete for the sequestration of trans-
acting factor and exosome, inhibiting in this way the target mRNA
degradation (37).
The p38 MAPK signaling pathway plays an important role in
inflammation and other physiological processes. There are four p38
MAPKs: α and β, which are 75% homologous, and γ and δ wich are
more distant relatives. Inflamatory stimuli activate four major
intracellular signaling pathways: the nuclear factor-κB (NFκB)
pathways and the three MAPK pathways (ERK, JNK and p38). All
four drive transcription of inflammatory genes. The p38 pathway
is also involved in posttranscriptional regulation, and stabilizes
inflammatory response mRNAs and promotes their translation
through ARE in the 3’UTR of the mRNAs. Posttranscriptional
regulation of TNF-α and cyclooxygenase-2 mRNAs by p38 have been
extensively investigated and several examples were already shown
in this review. Because inhibiting p38 MAPK suppresses production
of key inflammatory mediators, it was obvious to search for
inhibitors of p38 MAPK for therapy of chronic inflammatory diseases
such as rheumatorid arthritis, Crohn’s disease, chronic obstructive
pulmonary disease and psoriasis. The most widely used are pyridinyl
imidazole compounds such as SB203580 and SB202190. The
potential of p38 as a drug target has led to development of large
collection of inhibitors by pharmaceutical companies. Preclinical
studies have largely used model of arthritis, and several inhibitors
are now in human trials. Adverse effects of inhibition are hard to
predict but immunosupression is likely. Targets upstream or
downstream could also be used to block the MAPK pathway although
to date they have not been reported (38).
Furthermore, a number of approaches that exploit RNA’s
structural dynamics and sequence-specific binding abilities (RNA
interference, antisense RNA) are already in place to modulate gene
expression. However, there is increasing need for developing
synthetic riboregulators that can be integrated into biological
networks to function with a wide array of genes and yield insights
into RNA-based cellular processes. Isaacs and colleagues were able
to engineer riboregulators that both repress and activate translation
ISABEL LÓPEZ DE SILANES Y MANEL ESTELLER AN. R. ACAD. NAC. FARM.
578
in vivo, enabling precise control of gene expression through highly
specific RNA-RNA interactions (39). Moreover, the administration of
riboregulators (3’UTR framents) such as the one from the prohibitin
RNA, effectively controlled tumor cellular proliferation in vivo and
induced systemic antitumor immunity in rat models (40).
FUTURE PERSPECTIVES
The examples given above represent compelling evidences for
the involvement of alterations in 3’UTR mediated functions in the
pathogenesis of different diseases and emphasize the notion that
control exerted via the 3’UTR mRNA is crucial for the correct
regulation of gene expression. A systematic search for «3’UTR-
mediated diseases» is needed since, in the past, virtually all efforts
were focused on the coding region. For instance, the involvement of
the 3’UTR in controlling mRNA translation during both male and
female gametogenesis and in early embryonic development, and as
such post-transcriptional controls are essential to these processes, it
is a reasonable assumption that certain reproductive disorders will
be found to belong to this class of diseases. Additionally, the
identification of putative additional «3’UTR-mediated diseases» will
require the improvement and development of new methods in vitro
and in vivo to assess the interaction between cis-elements and trans-
acting factors as well as their kinetics. A more detailed understanding
of 3’UTR regulatory events through increased efforts directed
towards the study of this region and the development of adequate
analytical methods will aid in the design of novel chemotherapeutic
venues.
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